IgA肾病靶向治疗研究进展
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v6i5.10080
Abstract
IgA肾病(IgAN)是中国最常见的原发性肾小球疾病,也是导致终末期肾病的主要原因之一,目前没有特效治疗方法,临床上大多以支持疗法和免疫抑制疗法为主,但治疗作用局限,且毒副作用较大。近年来,随着对IgAN发病机理的深入研究,出现了许多针对发病机理的靶向新药。此类靶向新药有助于降低IgAN发展为慢性肾衰竭的可能性。以下是对IgA肾病靶向治疗新进展的综述。
Keywords
IgA肾病；靶向药物；治疗
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Chang JH, Kim DK, Kim HW, Park SY, Yoo TH, Kim BS, Kang SW, Choi KH, Han DS, Jeong HJ, Lee HY. Changing prevalence of glomerular diseases in Korean adults: a review of 20 years of experience.Nephrol Dial Transplant. 2009 Aug; 24(8): 2406-10.
[2] Wei M, Guo WY, Xu BY, Shi SF, Liu LJ, Zhou XJ, Lv JC, Zhu L, Zhang H. Collectin11 and Complement Activation in IgA Nephropathy.Clin J Am Soc Nephrol.2021Dec;16(12):1840-1850.
[3] Wang D, Wu C, Chen S, Li Y, Wang L, Zhang Y, Li G. Urinary complement profile in IgA nephropathy and its correlation with the clinical and pathological characteristics. Front Immunol.2023 Mar20;14:1117995.
[4] Rizk DV, Rovin BH,Zhang H,Kashihara N, Maes B, Trimarchi H, Perkovic V, Meier M, Kollins D, Papachristofi O, Charney A, Barratt J. Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study. Kidney Int Rep.2023Feb9;8(5):968- 979.
[5] Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.Int Rev Immunol. 2017 Jan 2;36(1):3-19.
[6] Mathur M, Barratt J,Suzuki Y.Safety,Tolerability,Pharm acokinetics,and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney Int Rep.2022 Feb 8;7(5):993-1003.
[7] Williams CEC, Lamond M. A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP).Clin Rheumatol.2023 Dec;42(12):3189-3200.
[8] Stefan G,Mircescu G.Hydroxychloroquine in IgA nephro pathy:a systematic review.Ren Fail.2021Dec;43(1):1520-1527.
[9] Hartono C,Chung M,Perlman AS.Bortezomib for Reducti on of Proteinuria in IgA Nephropathy. Kidney Int Rep. 2018 Mar11;3(4):861-866.
[10] Rosenblad T, Rebetz J, Johansson M, Békássy Z, Sartz L, Karpman D. Eculizumab treatment for rescue of renal function in IgA nephropathy. PediatrNephrol. 2014 Nov; 29(11):2225-8.
[11] Smerud HK, Bárány P, Lindström K, Fernström A,Sandell A, Påhlsson P, Fellström B. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria.Nephrol Dial Transplant. 2011 Oct;26(10):3237-42.
[12] Di Leo V, Gleeson PJ, Sallustio F, Bounaix C, Da Silva J, Loreto G, Ben Mkaddem S, Monteiro RC. Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice Model.J Pers Med.2021Apr16;11(4):309.
[2] Wei M, Guo WY, Xu BY, Shi SF, Liu LJ, Zhou XJ, Lv JC, Zhu L, Zhang H. Collectin11 and Complement Activation in IgA Nephropathy.Clin J Am Soc Nephrol.2021Dec;16(12):1840-1850.
[3] Wang D, Wu C, Chen S, Li Y, Wang L, Zhang Y, Li G. Urinary complement profile in IgA nephropathy and its correlation with the clinical and pathological characteristics. Front Immunol.2023 Mar20;14:1117995.
[4] Rizk DV, Rovin BH,Zhang H,Kashihara N, Maes B, Trimarchi H, Perkovic V, Meier M, Kollins D, Papachristofi O, Charney A, Barratt J. Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study. Kidney Int Rep.2023Feb9;8(5):968- 979.
[5] Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.Int Rev Immunol. 2017 Jan 2;36(1):3-19.
[6] Mathur M, Barratt J,Suzuki Y.Safety,Tolerability,Pharm acokinetics,and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney Int Rep.2022 Feb 8;7(5):993-1003.
[7] Williams CEC, Lamond M. A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP).Clin Rheumatol.2023 Dec;42(12):3189-3200.
[8] Stefan G,Mircescu G.Hydroxychloroquine in IgA nephro pathy:a systematic review.Ren Fail.2021Dec;43(1):1520-1527.
[9] Hartono C,Chung M,Perlman AS.Bortezomib for Reducti on of Proteinuria in IgA Nephropathy. Kidney Int Rep. 2018 Mar11;3(4):861-866.
[10] Rosenblad T, Rebetz J, Johansson M, Békássy Z, Sartz L, Karpman D. Eculizumab treatment for rescue of renal function in IgA nephropathy. PediatrNephrol. 2014 Nov; 29(11):2225-8.
[11] Smerud HK, Bárány P, Lindström K, Fernström A,Sandell A, Påhlsson P, Fellström B. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria.Nephrol Dial Transplant. 2011 Oct;26(10):3237-42.
[12] Di Leo V, Gleeson PJ, Sallustio F, Bounaix C, Da Silva J, Loreto G, Ben Mkaddem S, Monteiro RC. Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice Model.J Pers Med.2021Apr16;11(4):309.
Copyright © 2024 方霄宇, 贾利敏
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License